semaglutide label Doctors Petition FDA for Labeling Changes on Wegovy It works by controlling your appetite. FDA warns about compounded versions

The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events

Wilcoxon matched pairs signed rank test was used for non-parametric data

GHK-Cu has a favorable safety profile in published research with low rates of adverse events

This is a fundamentally different type of appetite suppression than what GLP-1 agonists provide

Cancer 8 , 28762884 (2017)

This is actually an advantage